From the National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland (Dr Larkin); and the National Ophthalmic Pathology Laboratory of Ireland (Ms Gleeson and Dr Kennedy), the Research Foundation (Ms Gleeson and Dr Kennedy), and the Department of Ophthalmology (Mr Horgan), Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
Arch Pathol Lab Med. 2014 May;138(5):664-70. doi: 10.5858/arpa.2012-0747-OA.
Loss of 1 copy of chromosome 3 is considered a significant indicator of metastatic dissemination in uveal melanoma. Fresh or paraffin-embedded tumor tissue is most commonly used for current cytogenetic techniques for determining chromosome 3 status in uveal melanoma and often requires referral to an external specialist laboratory for analysis.
To assess the chromogenic in situ hybridization assay for detecting chromosome 3 alterations using frozen tumor imprints and to compare the results obtained with those obtained by standard fluorescence in situ hybridization or single-nucleotide polymorphism array techniques.
Chromogenic in situ hybridization was performed on 52 frozen uveal melanoma tumor imprints. The genetic status of 26 of the 52 cases had been determined previously by fluorescence in situ hybridization (group 1); the status of 26 cases had been determined using single-nucleotide polymorphism array (group 2).
Chromogenic in situ hybridization was successfully performed on 48 of 52 tumor imprints. Chromogenic in situ hybridization showed excellent agreement in all 24 cases determined by fluorescence in situ hybridization (100% concordance; κ = 1; P < .001; 95% confidence interval, 100%-100%), and disagreed in 4 of the 24 cases previously studied by single-nucleotide polymorphism array (83% concordance; κ = 0.67; P < .001; 95% confidence interval, 95%-39%). All 4 discordant cases were classified as disomic for chromosome 3 by chromogenic in situ hybridization and monosomic by SNP array. On histologic examination, the 4 discordant cases corresponded to 2 mixed cell tumors and 2 spindle cell tumors.
Chromogenic in situ hybridization using tumor imprints is a reliable technique for determining chromosome 3 status in uveal melanoma. Furthermore, it can also be easily integrated into a routine histopathology laboratory.
1 号染色体缺失被认为是葡萄膜黑色素瘤转移扩散的重要指标。目前用于检测葡萄膜黑色素瘤 3 号染色体状态的细胞遗传学技术通常使用新鲜或石蜡包埋的肿瘤组织,并且通常需要转介到外部专家实验室进行分析。
评估使用冷冻肿瘤印痕进行染色体 3 改变的显色原位杂交检测,并将获得的结果与标准荧光原位杂交或单核苷酸多态性阵列技术的结果进行比较。
对 52 例冷冻葡萄膜黑色素瘤肿瘤印痕进行显色原位杂交。其中 26 例的遗传状态先前已通过荧光原位杂交确定(第 1 组);26 例的状态通过单核苷酸多态性阵列确定(第 2 组)。
52 例肿瘤印痕中的 48 例成功进行了显色原位杂交。在通过荧光原位杂交确定的 24 例中,显色原位杂交显示出极好的一致性(100%一致性;κ=1;P<0.001;95%置信区间,100%-100%),在先前通过单核苷酸多态性阵列研究的 24 例中有 4 例不一致(83%一致性;κ=0.67;P<0.001;95%置信区间,95%-39%)。所有 4 例不一致的病例均通过显色原位杂交分类为 3 号染色体的二倍体,而通过 SNP 阵列分类为单体型。在组织学检查中,4 例不一致的病例对应于 2 例混合细胞肿瘤和 2 例梭形细胞肿瘤。
使用肿瘤印痕的显色原位杂交是一种可靠的技术,可用于确定葡萄膜黑色素瘤的 3 号染色体状态。此外,它还可以很容易地整合到常规组织病理学实验室中。